H.C. Wainwright Maintains a Buy on Halozyme Therapeutics (HALO), Keeps the PT at $90
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Mitchell Kapoor maintained a Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO) on October 21, keeping the associated price target the same at $90. Is Halozyme Therapeutics, Inc. (HALO) the Unstoppable Growth Stock to Invest in Now? The analyst … Read more